Yoshiyuki Takami

Prof. Dr. Yoshiyuki Takami

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2019 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
YSYusuke Sakurai
Yusuke Sakurai
Yoshiyuki TakamiYoshiyuki Takami
Yoshiyuki Takami
KAKentaro Amano
Kentaro Amano
YHYoshiro Higuchi
Yoshiro Higuchi
KAKiyotoshi Akita
Kiyotoshi Akita
YTYasushi Takagi
Yasushi Takagi

19 January 2018 in The Thoracic and Cardiovascular Surgeon
Verified
Journal Article
Closed access
PDF file
YTYasushi Takagi
Yasushi Takagi
Yoshiyuki TakamiYoshiyuki Takami
Yoshiyuki Takami
Transit-time flow measurement (TTFM) has been increasingly applied to detect graft failure during coronary artery bypass grafting (CABG), because TTFM is less invasive, more reproducible, and less time consuming. Many authors have attempted to validate TTFM and to gain the clear cutoff values and algorithm in TTFM to predict graft failure. The TTFM technology has also been shown to be a useful tool to investigate CABG graft flow characteristics and coronary circulation physiology. It is important to recognize the practical roles of TTFM in the cardiac operating room by review and summarize the literatures.

12 November 1996 in Artificial Organs
Verified
Journal Article
Closed access
PDF file
Yoshiyuki TakamiYoshiyuki Takami
Yoshiyuki Takami
KMKenzo Makinouchi
Kenzo Makinouchi
TNTadashi Nakazawa
Tadashi Nakazawa
JGJulie Glueck
Julie Glueck
RBRobert Benkowski
Robert Benkowski
YNYukihiko Nose
Yukihiko Nose

1 January 2021 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
MNMika Noda
Mika Noda
Yoshiyuki TakamiYoshiyuki Takami
Yoshiyuki Takami
KAKentaro Amano
Kentaro Amano
YSYusuke Sakurai
Yusuke Sakurai
KAKiyotoshi Akita
Kiyotoshi Akita
YTYasushi Takagi
Yasushi Takagi

27 May 2018 in The International Journal of Artificial Organs
Verified
Journal Article
Closed access
Yoshiyuki TakamiYoshiyuki Takami
Yoshiyuki Takami
NHNaoki Hoshino
Naoki Hoshino
YKYasuchika Kato
Yasuchika Kato
YSYusuke Sakurai
Yusuke Sakurai
KAKentaro Amano
Kentaro Amano
YOYukio Ozaki
Yukio Ozaki
Introduction: Ventricular assist device is used in the patients with severe heart failure due to cardiotoxicity of anthracyclines, which are widely used chemotherapeutic agents for a wide range of malignant tumors. However, recovery of cardiac function is rare. Methods: We present the clinical course of a 43-year-old woman in remission from diffuse large B-cell lymphoma after the chemotherapy including anthracyclines, who presented in cardiogenic shock 8 months after the end of chemotherapy. Results: The patient was initially treated with intra-aortic balloon pumping, followed by conversion to left ventricular assist device with an Abiomed AB5000 (Abiomed, Inc, Danvers, MA) and right ventricular assist device with a centrifugal pump and a membrane oxygenator, in addition to tricuspid annuloplasty, due to rapid deterioration to cardiogenic shock. With intensive medical treatments during biventricular support, her cardiac and respiratory functions gradually improved, although moderate mitral regurgitation persisted despite of left ventricular unloading. At 64 days of biventricular support, she underwent mitral valve annuloplasty to correct regurgitation under cardiopulmonary bypass. She was consequently weaned from biventricular assist successfully 8 days after mitral surgery (72 days of biventricular support). The patient discharged uneventfully from our hospital and survives at home 12 months after weaning from the ventricular assist devices. Conclusion: Our case and the literature review highlight potential usefulness of aggressive mechanical biventricular support for cardiac recovery in patients with anthracycline-induced cardiomyopathy. Additional valve surgery and neurohormonal medications may be also promising in such patients with cancer, who are contraindicated for heart transplantation.

6 May 2022 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
RHRyosuke Hayashi
Ryosuke Hayashi
Yoshiyuki TakamiYoshiyuki Takami
Yoshiyuki Takami
HFHidetsugu Fujigaki
Hidetsugu Fujigaki
KAKentaro Amano
Kentaro Amano
YSYusuke Sakurai
Yusuke Sakurai
YTYasushi Takagi
Yasushi Takagi
Patients with cardiovascular disease are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection. Although SARS-CoV2 vaccination may be effective, its impact on surgical patients is not well studied. We investigated the effects of cardiovascular surgery, especially under cardiopulmonary bypass (CPB), on the antibody titres after SARS-CoV2 vaccination. A prospective observational study was designed for patients undergoing surgery between July and November 2021. The immunoglobulin G against the receptor-binding domain was measured and antibody preserved rate (APR) was calculated from perioperative titres comparison. Enrolled 63 study patients were divided into 39 undergoing surgery with CPB (Group CPB) and 24 without CPB (Group None). Preoperative vaccines were BNT162b2 (Pfizer/BioNTech) (n = 58, 92%) and mRNA-1273 (Moderna) (n = 5, 8%). While immunoglobulin G against the receptor-binding domain titres did not significantly decrease after surgery in Group None, they decreased significantly in Group CPB from 21.80 [11.15, 37.85] to 11.95 [6.80, 18.18] U/ml (P < 0.001) a day after surgery, 11.40 [7.85, 22.65] U/ml (P < 0.001) 14 days after surgery and 7.60 [4.80, 17.60] U/ml (P < 0.001) a month after surgery. The APRs a day after the surgery were significantly lower in Group CPB (0.46 [0.41, 0.60]) than in Group None (0.80 [0.68, 0.87]) (P < 0.001). The SARS-CoV2 antibody titres significantly decreased with lower APRs immediately after surgery under CPB. Based on our informative results, careful considerations of vaccination schedule might be required for surgery under CPB.